Trav16d inhibitors are a class of chemical compounds specifically designed to target and inhibit the activity of the Trav16d protein or receptor. These inhibitors function by binding to the active site of the Trav16d protein, blocking its interaction with natural substrates or ligands, and thereby preventing the protein from performing its normal biological functions. In some cases, these inhibitors may also bind to allosteric sites, which are regions on the protein separate from the active site. Binding to these allosteric sites induces conformational changes in the Trav16d protein, altering its structural configuration and reducing its ability to carry out its function. The interaction between Trav16d inhibitors and the protein is stabilized by various non-covalent forces, including hydrogen bonding, van der Waals interactions, electrostatic forces, and hydrophobic contacts. These forces ensure the inhibitor's stability within the binding pocket and enhance its ability to modulate the protein's activity effectively.
Trav16d inhibitors display a wide range of structural diversity, from small organic molecules to more complex chemical frameworks. These inhibitors often feature key structural elements such as aromatic rings, heterocycles, and functional groups like hydroxyl, carboxyl, or amine groups, which play a crucial role in facilitating specific interactions with the Trav16d protein. The design of these inhibitors involves optimizing physicochemical properties such as molecular weight, polarity, solubility, and lipophilicity to ensure adequate binding affinity and selectivity for Trav16d. Hydrophobic regions within the inhibitor structure can interact with non-polar pockets of the protein, while polar or charged groups can form hydrogen bonds or ionic interactions with polar residues within the Trav16d protein's binding site. By carefully balancing these properties, Trav16d inhibitors are designed to achieve strong and selective binding, ensuring effective modulation of Trav16d's activity while maintaining stability and solubility in various biological environments.
SEE ALSO...
Items 1 to 10 of 12 total
Display:
Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
---|---|---|---|---|---|---|
Staurosporine | 62996-74-1 | sc-3510 sc-3510A sc-3510B | 100 µg 1 mg 5 mg | $82.00 $150.00 $388.00 | 113 | |
Staurosporine inhibits protein kinase C, which could lead to reduced phosphorylation activity on Trav16d, assuming Trav16d is a substrate for PKC-mediated phosphorylation. | ||||||
Wortmannin | 19545-26-7 | sc-3505 sc-3505A sc-3505B | 1 mg 5 mg 20 mg | $66.00 $219.00 $417.00 | 97 | |
Wortmannin is a PI3K inhibitor, and PI3K signaling often leads to activation of downstream kinases that could phosphorylate Trav16d; inhibition here could reduce Trav16d activity. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $121.00 $392.00 | 148 | |
LY294002 also inhibits PI3K, similar to Wortmannin, potentially reducing kinase activity downstream that could phosphorylate and activate Trav16d. | ||||||
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $39.00 $90.00 | 212 | |
PD98059 inhibits MEK, which is upstream of ERK; if Trav16d functions downstream of this pathway, its activity could be diminished due to reduced ERK activation. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $88.00 $342.00 | 284 | |
SB203580 selectively inhibits p38 MAP kinase; if Trav16d is activated by p38 MAPK signaling, this inhibition could reduce its functional activity. | ||||||
SP600125 | 129-56-6 | sc-200635 sc-200635A | 10 mg 50 mg | $65.00 $267.00 | 257 | |
SP600125 is an inhibitor of JNK, which, if Trav16d operates downstream of JNK signaling, would lead to decreased Trav16d activity due to reduced activation by JNK. | ||||||
U-0126 | 109511-58-2 | sc-222395 sc-222395A | 1 mg 5 mg | $63.00 $241.00 | 136 | |
U0126 inhibits MEK1/2, similar to PD98059, and could reduce ERK pathway signaling, potentially decreasing Trav16d activity if it is regulated by this pathway. | ||||||
PP 2 | 172889-27-9 | sc-202769 sc-202769A | 1 mg 5 mg | $92.00 $223.00 | 30 | |
PP2 is an Src family kinase inhibitor; if Trav16d is phosphorylated by Src kinases, its activity could be reduced by this inhibition. | ||||||
Dasatinib | 302962-49-8 | sc-358114 sc-358114A | 25 mg 1 g | $47.00 $145.00 | 51 | |
Dasatinib broadly inhibits Src family kinases and Bcr-Abl; inhibition of these kinases might reduce phosphorylation of Trav16d, thereby decreasing its activity. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $62.00 $155.00 $320.00 | 233 | |
Rapamycin inhibits mTOR, which can affect protein synthesis and kinase signaling; reduced mTOR activity could lead to less functional Trav16d through reduced signaling. |